Anakinra is a recombinant, nonglycosylated human interleukin-1 receptor antagonist (IL-1Ra). The difference between anakinra and the native human IL-1Ra is that anakinra has an extra methionine residue at the amino terminus. It is manufactured by using the E. coli expression system. Anakinra is composed of 153 amino acid residues. FDA approved on November 14, 2001.

Price Not Available 1 mg Anakinra Supplier Page
Trivial name IL1RN
Catalog Number TP-085CL
Alternative Name(s) Anakinra
Research Area Immunoregulation
Molecular Formula C759H1186N208O232S10
CAS# 143090-92-0
Purity >90%
Size 1 mg
Supplier Page
Additional Information For the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID).